Clinical Trials | December 12, 2025
Neurizon’s ALS drug regimen cleared for launch in Healey platform trial
The Healey ALS Platform Trial is a multicenter, double-blind, placebo-controlled
The Healey ALS Platform Trial is a multicenter, double-blind, placebo-controlled
The multi-partner team will integrate new technologies across the entire mAb production workflow, from cell line development to purification
The FDA aims to make a decision by April 8, 2026
The U.S. oncology market is projected to soar from $81 billion in 2025 to $212 billion by 2034
The companies aim to expand treatment options for millions living with metabolic disorders
This is the first approval of a prescription transdermal dosage Form in the European markets from this facility
The product will be marketed by Dr. Reddy's Laboratories Inc.
Roche says its new assay “resolves this challenge by delivering accurate and specific results
The approval follows strong results from Roche’s phase II NOBILITY and phase III REGENCY studies
Golcadomide, a CELMoD agent, continued to deliver deep and durable responses in aggressive B-cell and follicular lymphomas
Subscribe To Our Newsletter & Stay Updated
